Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

What happened: Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O'Sullivan will present data on Why it matters: Artelo describes ART26.12 as the first selective FABP5 inhibitor to enter human clinical studies, and the company says it is preparing to begin enrollment in the MAD study as the next development step. Summary: Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on ART26.12, described as the first selective FABP5 inhibitor to enter human clinical studies, at the IASP 2026 World Congress on Pain in Bangkok on October 29, 2026.

Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O'Sullivan will present data on

Artelo describes ART26.12 as the first selective FABP5 inhibitor to enter human clinical studies, and the company says it is preparing to begin enrollment in the MAD study as the next development step. Summary: Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on ART26.12, described as the first selective FABP5 inhibitor to enter human clinical studies, at the IASP 2026 World Congress on Pain in Bangkok on October 29, 2026.